Diabetes Clinical Trial
Official title:
Perindopril vs Ramipril for Persistence in MAU Reduction Study
The investigators conducted a single center study controlled study involving 20 patients with Type 2 Diabetes and hypertension who were randomly assigned to receive ramipril 10mg or perindopril 8mg. The primary endpoint was difference in urine albumin-creatinine ratio at night time and during the day. Secondary endpoint was measurement of blood pressure.
Design/Method This was a single arm, prospective, randomized, single blinded, open label
cross-over study of the urine albumin excretion during the day and at night after 12 weeks
of therapy with either perindopril 8 mg per day or ramipril 10 mg per day in people with
diabetes. Men and women were eligible for the study if they met the following criteria:
Age>18 years, type 2 diabetes with adequate blood sugar control (Hemoglobin A1c (A1c)<8.4%),
therapy with ace inhibitor(ACEi) or angiotensin receptor blocker (ARB) for a period of 8
weeks prior to and throughout the screening period along with blood pressure (BP) <130/80
mmHg, known abnormal albuminuria for at least 12 weeks before screening and throughout the
screening period as defined as (urine albumin by albumin-creatinine ratio (ACR) > 5.0 for
men and women up to 50 mg/mmol).
Exclusion criteria included: women who were pregnant or lactating, women of childbearing age
not on contraception, dual therapy with both ARB and ACEi, 8 weeks prior to screening visit
or during screening period, allergy or history of cough with ACEi, known hypersensitivity to
study medication diluent or to any constituent of study medication, poorly controlled
hypertension (HTN) requiring a change of dose of ACEi or ARB within 8 weeks of screening
visit, change in urine albumin by ≥ 2x from a previous level to the screening level while on
stable drug dosing, myocardial infarction within 12 weeks of screening, congestive heart
failure (NYHA Class IV), severe coronary artery disease, severe liver disease, renal artery
stenosis.
Patients meeting the inclusion and exclusion criteria were enrolled in the study and
randomized. Following this, eligible patients were switched from their existing renin
angiotensin aldosterone system (RAAS) blocker to ramipril 10 mg daily for 1 week to
determine if ramipril was tolerated. They then were entered into a stabilization phase of 12
weeks of uninterrupted ramipril therapy. Patients were assigned to receive either
perindopril 8 mg once daily or 10 mg ramipril once daily based on the randomization code in
an open label fashion. Treatment with either therapy was for 12 weeks each. At the end of
these treatment periods patients were instructed to collect three sets of spot urine samples
to reflect night and day urine albumin excretion. Additionally, patients were instructed to
take four home blood pressure measurements, 2 in the morning and 2 in the evening. The
morning recordings were to be done before the medication was taken. At the end of the 12
week treatment periods, measurements of urine electrolytes, A1c, urea, creatinine were also
collected. A 24 hour ambulatory blood pressure monitoring (ABPM) was also completed at the
end of the last two treatment periods.
Laboratory Procedures:
Ambulatory blood pressure was measured was performed over a period of 24 hours using a
clinically validated device (model 90270, Spacelabs Medical Inc., Redmond, Washington, USA).
The machine was instructed to measure blood pressure every 15 minutes throughout the day
(7:00am to 11:00 PM) and every 30 minutes between 11:00pm and 7:00am. Patients were
instructed to remain motionless every time the device was active. Values obtained were
averaged each hour before calculating the day, night and average 24hr blood pressure.
During the 12th week of each treatment period, urine was collected from each patient to
quantitatively measure urine sodium, potassium, urea, creatinine. AER was measured from
urine collected under standard conditions. Three specimens were collected in each treatment
period and the results were analyzed by immunoassay.
Statistical Analysis:
Statistical analysis of data was performed by means of SAS statistical software for Windows
(SAS., Cary, North Carolina) with results being expressed as mean (SD).
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |